InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

September 8, 2022

https://www.globenewswire.com/news-release/2022/09/08/2512887/36215/en/InMed-Pharmaceuticals-Provides-Update-on-its-Core-Research-and-Development-Programs-and-BayMedica-Business.html

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces an update on its research/development and commercial activities.

Read more at globenewswire.com

Related news for (INM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.